Abstract 1648: Discovery of a potent and selective PARP1 inhibitor and trapper with anti-tumor activities in HRD tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1648
Abstract: PARP1/2 inhibitors are FDA approved for treatment of cancers such as ovarian, prostate, pancreas and breast with greatest activity against tumors harboring BRCA1 or 2 mutation or homologous recombination deficiency (HRD). A shared adverse event… read more here.
Keywords: parp1 inhibitor; selective parp1; parp1; inhibitor trapper ... See more keywords
MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2021.12187
Abstract: Triple-negative breast cancer (TNBC) is the most common type of cancer among females worldwide and is associated with poor prognosis. Poly ADP-ribose polymerase-1 (PARP1) inhibitors are effective against TNBC with mutations in the breast cancer… read more here.
Keywords: protein; parp1 inhibitor; breast; breast cancer ... See more keywords